

Clinical Trial Protocol

Iranian Registry of Clinical Trials

24 Jun 2026

Evaluation of the effect of Eplerenone in Central serous chorioretinopathy (CSCR)

Protocol summary

Study aim

Determination of the effect of Eplerenone in patients with chronic central serous chorioretinopathy (CSCR)

Design

In this study, patients will be randomly assigned to two groups of 17: treatment (administration of eplerenone) and control (placebo of neutral drug). Will be prescribed weekly. In the control group, placebo will be prescribed for 4 weeks.

Settings and conduct

Imam Khomeini Hospital In this study, patients were randomly assigned to two groups of 17 (treatment with Eplerenone) and control (placebo of neutral drug) and after the disease was diagnosed by an ophthalmologist, participants received medication or The placebo will be referred to the secretary and he (medicine or placebo) will be delivered to the patients in two groups. For patients in the intervention group, Eplerenone will be administered at a dose of 25 mg for one week and then at a dose of 50 mg for three weeks. In the control group, placebo will be prescribed for 4 weeks.

Participants/Inclusion and exclusion criteria

Acute onset of the disease (less than 3 months) No previous treatment, no pathology, no vision, normal kidney tests and exclusion criteria: renal and hepatic impairment, or known allergy to any of the components of the drug

Intervention groups

Patients in the intervention group will be prescribed Eplerenone at a dose of 25 mg for one week and then at a dose of 50 mg for three weeks. In the control group, placebo will be prescribed for 4 weeks.

Main outcome variables

Best modified vision, central macular thickness, macular volume, choroid thickness

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220122053792N1**

Registration date: **2022-03-06, 1400/12/15**

Registration timing: **registered_while_recruiting**

Last update: **2022-03-06, 1400/12/15**

Update count: **0**

Registration date

2022-03-06, 1400/12/15

Registrant information

Name

Qader Motarjemizadeh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 44 3346 9931

Email address

motarjemizadeh.q@umsu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-01-15, 1400/10/25

Expected recruitment end date

2022-07-16, 1401/04/25

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of Eplerenone in Central serous chorioretinopathy (CSCR)

Public title

Evaluation of the effect of Eplerenone in Central serous chorioretinopathy (CSCR)

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Patients with chronic central serous chorioretinopathy

Exclusion criteria:

Elevated potassium levels in preoperative blood tests or contraindications in comprehensive medical examination renal impairment severe hepatic impairment known allergies to any of the components of the drug

Age

No age limit

Gender

Both

Phase

1-2

Groups that have been masked

- Participant
- Care provider

Sample size

Target sample size: 34

Randomization (investigator's opinion)

Randomized

Randomization description

In this study, patients will be randomly divided into two groups of treatment (administration of Eplerenone) and control (placebo of neutral drug) with random allocation software (Random Allocation software).

Blinding (investigator's opinion)

Double blinded

Blinding description

606 / 5,000 Translation results In the present study, patients and the treatment team (physicians) had no knowledge that each patient was in the treatment group or placebo group. Patients will be divided into two groups of treatment or placebo based on randomization after their disease is diagnosed. Then, without knowing which group each patient is in, the researcher will enter the patient in the study and the relevant treatment will be started and will be visited for follow-up in the future. Patients also do not know which group they belong to until the end of the study period. After the person is diagnosed with the disease by an ophthalmologist, participants are referred to a secretary for medication or a placebo.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Urmia University of Medical Sciences

Street address

Imam Khomeini University Hospital-Ershad AVE-Modarres Blvd- Urmia-IRAN

City

Urmia

Province

West Azarbaijan

Postal code

5715789397

Approval date

2022-01-15, 1400/10/25

Ethics committee reference number

IR.UMSU.REC.1400.407

Health conditions studied**1****Description of health condition studied**

Chronic central serous chorioretinopathy

ICD-10 code

H35.71

ICD-10 code description

Central serous chorioretinopathy

Primary outcomes**1****Description**

The patient's best corrected vision

Timepoint

Before and one month after the start of the intervention

Method of measurement

snellen chart

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: For patients in the intervention group, Eplerenone will be administered at a dose of 25 mg for one week and then at a dose of 50 mg for three weeks.

Category

Treatment - Drugs

2**Description**

Control group: In the control group, placebo will be prescribed for 4 weeks.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Urmia University of Medical Sciences Imam Khomeini Hospital

Full name of responsible person

Dr. Qader Motarjemizadeh

Street address

Imam Khomeini University Hospital-Ershad AVE-Modarres Blvd- Urmia-IRAN

City

Urmia

Province

West Azarbaijan

Postal code

5715789397

Phone

+98 44 3346 9931

Fax

+98 44 3345 7277

Email

Motarjemizadeh.q@umsu.ac.ir

Web page address

<http://Imam.Umsu.ac.ir>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Oroumia University of Medical Sciences

Full name of responsible person

Dr. Saber Gholizadeh

Street address

Urmia, Resalat Blvd., Emergency Alley, West Azerbaijan University of Medical Sciences

City

Urmia

Province

West Azarbaijan

Postal code

5714783734

Phone

+98 44 3346 9931

Email

saber@umsu.ac.ir

Web page address

<http://Imam.umsu.ac.ir>

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Oroumia University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Oroumia University of Medical Sciences

Full name of responsible person

Dr. Qader Motarjemizadeh

Position

Associate Professor

Latest degree

Subspecialist

Other areas of specialty/work

Ophthalmology

Street address

Imam Khomeini University Hospital-Ershad AVE-Modarres Blvd- Urmia-IRAN

City

Urmia

Province

West Azarbaijan

Postal code

5715789397

Phone

0984433469931

Email

Motarjemizadeh.q@umsu.ac.ir

Web page address

<http://Imam.umsu.ac.ir>

Person responsible for scientific inquiries

Contact

Name of organization / entity

Oroumia University of Medical Sciences

Full name of responsible person

Dr. Qader Motarjemizadeh

Position

Associate Professor

Latest degree

Subspecialist

Other areas of specialty/work

Ophthalmology

Street address

Imam Khomeini University Hospital-Ershad AVE-Modarres Blvd- Urmia-IRAN

City

Urmia

Province

West Azarbaijan

Postal code

5715789397

Phone

+98 44 3346 9931

Email

Motarjemizadeh.q@umsu.ac.ir

Web page address

<http://Imam.Umsu.ac.ir>

Person responsible for updating data

Contact

Name of organization / entity

Oroumia University of Medical Sciences

Full name of responsible person

Dr. Qader Motarjemizadeh

Position

Associate Professor

Latest degree

Subspecialist

Other areas of specialty/work

Ophthalmology

Street address

Imam Khomeini University Hospital-Ershad AVE-
Modarres Blvd- Urmia-IRAN

City

Urmia

Province

West Azarbaijan

Postal code

5715789397

Phone

+98 44 3346 9931

Email

Motarjemizadeh.q@umsu.ac.ir

Web page address

<http://Imam.Umsu.ac.ir>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available